Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents

被引：0
|
作者：
Finn, R. S.
Lau, A.
Kalous, O.
Conklin, D.
Dering, J.
Knights, C.
O'Shaughnessy, A.
Cranston, A.
Riches, L.
Carmichael, J.
O'Connor, M. J.
Slamon, D. J.
机构：
[1] KuDOS Pharmaceut, Cambridge, England
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117S / 117S
页数：1
相关论文
共 50 条
  • [21] Combination of epigenetic, differentiation and DNA damaging agents induce tumor cell death and stem cell depletion in breast cancer
    Merino, Vanessa F.
    Nguyen Nguyen
    Sadik, Helen
    Cho, Soonweng
    Cope, Leslie
    Zhou, Xian C.
    Zhang, Zhe
    Chen, Qian
    Pan, Duojia
    Huso, David L.
    Ali, Syed
    Adams, Christina
    Gyorffy, Balazs
    Sukumar, Saraswati
    CANCER RESEARCH, 2015, 75
  • [22] Niraparib, a selective PARP 1/2 inhibitor, is efficacious in pre-clinical models of small-cell lung cancer
    Wang, Y.
    Ricono, J.
    Admunson, K.
    Agarwal, S.
    Fram, R. J.
    Broudy, T.
    Wilcoxen, K. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 80 - 81
  • [23] Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
    Dent, R. A.
    Lindeman, G. J.
    Clemons, M.
    Wildiers, H.
    Chan, A.
    McCarthy, N. J.
    Singer, C. F.
    Lowe, E. S.
    Kemsley, K.
    Carmichael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] EFFECTS OF DNA-DAMAGING AGENTS ON GENE-EXPRESSION IN 2 HUMAN CANCER CELL-LINES
    VIKHANSKAYA, F
    DINCALCI, M
    BROGGINI, M
    CELLULAR AND MOLECULAR BIOLOGY, 1993, 39 (08) : 855 - 862
  • [25] Inhibition of growth of human breast cancer cell lines with the combination of an mTOR inhibitor and a Bcl-2 inhibitor
    Wilson, Matthew
    Witters, Lois
    Lane, Heidi
    Lipton, Allan
    CANCER RESEARCH, 2006, 66 (08)
  • [26] The use of poly(ADP-ribose) polymerase (PARP1) inhibitors (AG14361, AZD2281, ABT888) in combination with capecitabine, 5-fluorouracil, or paclitaxel in the treatment of hereditary and sporadic breast and ovarian cancer
    De Soto, J. A.
    Quick-Fountain, R.
    Velikodvorskaya, T.
    Fatima, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer
    Street, I.
    de Sylva, M.
    Lackovic, K.
    Ganame, D.
    Holloway, G.
    Anderson, R.
    McArthur, G.
    Natoli, A.
    Doherty, J.
    Falk, H.
    Kersten, W.
    Lessene, R.
    Leuchowius, K.
    Novello, P.
    Yang, H.
    Bergman, Y.
    Camerino, M.
    Charman, S.
    Gregg, A.
    Choi, N.
    Foitzik, R.
    Hemley, C.
    Lunniss, G.
    Nikac, M.
    Walker, S.
    Lovrecz, G.
    Monahan, B.
    Peat, T.
    Robinson, C.
    Scott, C.
    Gorman, M.
    Parker, M.
    Holmes, I.
    Devlin, M.
    CANCER RESEARCH, 2012, 72
  • [28] Pre-clinical evaluation of the farnesyltransferase inhibitor SCH 66336, in non-small cell lung cancer (NSCLC) cell lines.
    Loprevite, M
    Favoni, RE
    Mazzanti, P
    de Cupis, A
    Pirani, P
    Grossi, F
    Ardizzoni, A
    CLINICAL CANCER RESEARCH, 2000, 6 : 4546S - 4546S
  • [29] Recombinant Human Erythropoietin (rHuEPO) In Combination with Chemotherapy Increases Breast Cancer Metastasis In Pre-Clinical Mouse Models.
    Xenocostas, Anargyros
    Hedley, Benjamin D.
    Chu, Jenny E.
    Ormond, D. George
    Beausoleil, Michel
    Boasie, Alexandra
    Allan, Alison L.
    BLOOD, 2010, 116 (21) : 1370 - 1370
  • [30] Pre-clinical activity of the Wnt pathway inhibitor RXC004 in combination with MAPK pathway inhibitors in GI cancer models
    Woodcock, Simon A.
    Keppel, Dorottya
    Eagle, Catherine
    Kelly, James
    Flanagan, Eimear
    Bishop, Emma
    Bhamra, Inder
    Jones, Clifford D.
    Armer, Richard
    Robertson, Jane
    Phillips, Caroline
    CANCER RESEARCH, 2024, 84 (06)
12345